Purpose: Adenosine deaminase (ADA) deficiency is a systemic disorder of purine metabolism. Deficiency of the purine salvage enzyme ADA leads to the build-up of the toxic metabolites, deoxyadenosine triphosphate and deoxyadenosine. ADA is ubiquitously expressed in all tissues of the body but most profoundly affects lymphocyte development and function leading to severe combined immunodeficiency (SCID). Unlike most other forms of SCID, ADA deficiency also results in non-immunologic manifestations. Associations between ADA deficiency and sensorineural hearing loss, behavioural abnormalities, non-infectious pulmonary disease and skeletal dysplasia are all recognised, and affect the long term outcome for these patients. Identification of new non-immunological manifestations and clinical presentations of ADA deficiency is essential to allow early optimisation of supportive care.
Methods And Results: Here we report four patients with ADA deficiency whose presenting feature was haemolytic uremic syndrome (HUS). 3 of 4 patients were diagnosed with ADA deficiency only after developing HUS, and one diagnosis was made post mortem, after a sibling was diagnosed with SCID. Shiga-toxigenic organisms were not isolated from any of the patients. 2 patients made a good recovery from their HUS with supportive treatment and initiation of PEG-ADA. Both remain well on enzyme replacement with mild or no residual renal impairment.
Conclusions: Clinicians should be aware of this previously unreported non-immunologic manifestation of ADA deficiency.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10875-015-0158-0 | DOI Listing |
Curr Opin Rheumatol
January 2025
Marmara University School of Medicine, Department of Dermatology, Istanbul, Türkiye.
Clin Immunol
January 2025
Department of Child Health and Development, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan. Electronic address:
Adenosine deaminase (ADA) deficiency typically presents as a severe combined immunodeficiency in early infancy, although its onset may be delayed in some cases. We encountered two patients diagnosed with ADA deficiency in adulthood. In addition to previously reported cases, we aimed to identify and characterize the clinical and immunological features associated with delayed- and late-onset ADA deficiency.
View Article and Find Full Text PDFJ Clin Immunol
September 2024
Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, University of Freiburg, Faculty of Medicine, Freiburg, Germany.
J Allergy Clin Immunol
January 2025
Department of Medicine, Division of Rheumatology and Immunology, Duke University School of Medicine, Durham, NC; Department of Biochemistry, Duke University School of Medicine, Durham, NC. Electronic address:
Background: Deficiency of adenosine deaminase (ADA or ADA1) has broad clinical and genetic heterogeneity. Screening techniques can identify asymptomatic infants whose phenotype and prognosis are indeterminate, and who may carry ADA variants of unknown significance.
Objective: We systematically assessed the pathogenic potential of rare ADA missense variants to better define the relationship of genotype to red blood cell (RBC) total deoxyadenosine nucleotide (dAXP) content and to phenotype.
Turk J Haematol
August 2024
Hacettepe University Faculty of Medicine, Department of Pediatric Hematology, Ankara, Türkiye
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!